Richard Görg

Richard Görg

Auto-generated profile, based on publicly available information

Richard Görg

Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, 13 Göttingen, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JPJulian Palzer
Julian Palzer
BMBenedikt Mues
Benedikt Mues
RGRichard Goerg
Richard Goerg
MAMerel Aberle
Merel Aberle
SRSander S Rensen
Sander S Rensen
ARAnjali A. Roeth
Anjali A. Roeth
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a meager prognosis due to its chemotherapy resistance. A new treatment method may be magnetic fluid hyperthermia (MFH). Magnetoliposomes (ML), consisting of superparamagnetic iron oxide nanoparticles (SPION) stabilized with a phospholipid-bilayer, are exposed to an alternating magnetic field (AMF) to generate heat. To optimize this therapy, we investigated the effects of MFH on human PDAC cell lines and 3D organoid cultures. Material and Methods: ML cytotoxicity was tested on Mia PaCa-2 and PANC-1 cells and on PDAC 3D organoid cultures, generated from resected tissue of patients. The MFH was achieved by AMF application with an amplitude of 40– 47 kA/m and a frequency of 270 kHz. The MFH effect on the cell viability of the cell lines and the organoid cultures was investigated at two different time points. Clonogenic assays evaluated the impairment of colony formation. Altering ML set-ups addressed differences arising from intra- vs extracellular ML locations. Results: Mia PaCa-2 and PANC-1 cells showed no cytotoxic effects at ML concentrations up to 300 μg(Fe)/mL and 225 μg(Fe)/mL, respectively. ML at a concentration of 225 μg(Fe)/mL were also non-toxic for PDAC organoid cultures. MFH treatment using exclusively extracellular ML presented the highest impact on cell viability. Clonogenic assays demonstrated remarkable impairment as long-term outcome in MFH-treated PDAC cell lines. Additionally, we successfully treated PDAC organoids with extracellular ML-derived MFH, resulting in notably reduced cell viabilities 2h and 24 h post treatment. Still, PDAC organoids seem to partly recover from MFH after 24 h as opposed to conventional 2D-cultures. Conclusion: Treatment with MFH strongly diminished pancreatic cancer cell viability in vitro, making it a promising treatment strategy. As organoids resemble the more advanced in vivo conditions better than conventional 2D cell lines, our organoid model holds great potential for further investigations.

15 November 2024 in Science Advances
Verified
Journal Article
Open access
HCHyun-Kyu Choi
Hyun-Kyu Choi
STStefano Travaglino
Stefano Travaglino
MMMatthias Münchhalfen
Matthias Münchhalfen
RGRichard Görg
Richard Görg
ZZZhe Zhong
Zhe Zhong
CZCheng Zhu
Cheng Zhu
B cell maturation depends on cognate interactions between the T and B cells. Upon interaction with CD40 ligand (CD40L) on T cells, CD40 delivers costimulatory signals alongside B cell antigen receptor (BCR) signaling to regulate affinity maturation and antibody class switch. Mutations affecting CD40-CD40L interactions cause abnormal antibody responses in immunodeficiencies known as X-linked hyper-IgM syndrome (X-HIgM). Here, we study the CD40-mediated mechanotransduction in B cells, which likely occurs during their physical contacts with T cells. We found that CD40 forms catch bond with CD40L that lasts longer at larger forces, both B and T cells exert tension on CD40-CD40L bonds, and force enhances CD40 signaling and antibody class switch. X-HIgM CD40L mutations impair catch bond formation, suppress endogenous tension, and reduce force-enhanced CD40 signaling, leading to deficiencies in antibody class switch. Our findings highlight the role of mechanotransduction in CD40 function and provide insights into the mechanisms underlying X-HIgM syndrome.

14 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMatthias Münchhalfen
Matthias Münchhalfen
RGRichard Görg
Richard Görg
MHMichael Haberl
Michael Haberl
JLJens Löber
Jens Löber
JWJakob Willenbrink
Jakob Willenbrink
JWJürgen Wienands
Jürgen Wienands
Ligation of the B cell antigen receptor (BCR) initiates humoral immunity. However, BCR signaling without appropriate co-stimulation commits B cells to death rather than to differentiation into immune effector cells. How BCR activation depletes potentially autoreactive B cells while simultaneously primes for receiving rescue and differentiation signals from cognate T lymphocytes remains unknown. Here, we use a mass spectrometry-based proteomic approach to identify cytosolic/nuclear shuttling elements and uncover transcription factor EB (TFEB) as a central BCR-controlled rheostat that drives activation-induced apoptosis, and concurrently promotes the reception of co-stimulatory rescue signals by supporting B cell migration and antigen presentation. CD40 co-stimulation prevents TFEB-driven cell death, while enhancing and prolonging TFEB’s nuclear residency, which hallmarks antigenic experience also of memory B cells. In mice, TFEB shapes the transcriptional landscape of germinal center B cells. Within the germinal center, TFEB facilitates the dark zone entry of light-zone-residing centrocytes through regulation of chemokine receptors and, by balancing the expression of Bcl-2/BH3-only family members, integrates antigen-induced apoptosis with T cell-provided CD40 survival signals. Thus, TFEB reprograms antigen-primed germinal center B cells for cell fate decisions.

14 October 2023 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
RGRichard Görg
Richard Görg
ABAnna Büttgenbach
Anna Büttgenbach
JJJana Jakobs
Jana Jakobs
FBFatıma Hacer Kurtoğlu Babayev
Fatıma Hacer Kurtoğlu Babayev
BRBenjamin Rolles
Benjamin Rolles
IWInga Wessels
Inga Wessels

6 September 2022 in Research Square
Verified
Preprint
Open access
PDF file
JWJürgen Wienands
Jürgen Wienands
MMMatthias Münchhalfen
Matthias Münchhalfen
RGRichard Görg
Richard Görg
JLJens Löber
Jens Löber
JWJakob Willenbrink
Jakob Willenbrink
NENiklas Engels
Niklas Engels
Ligation of the B cell antigen receptor (BCR) initiates humoral immunity. However, mere BCR signaling without subsequent co-stimulation by T cells commits B cells to death rather than to differentiation into immune effector cells. It remains mysterious how the BCR simultaneously executes the opposing roles of B cell priming necessary for proper immune responsiveness and elimination of potentially autoreactive B cells deprived of co-stimulatory signals. Here, we uncover transcription factor EB (TFEB) as a hitherto unknown BCR effector and central rheostat that drives antigen-induced apoptosis, and in parallel, renders primed B cells responsive to co-stimulatory rescue signals through promotion of lymphocyte migration and antigen presentation. Balanced integration of BCR-induced death with survival signals occurs at the converging point of Bcl-xL-controlled apoptosis rather than autophagic circuits for which TFEB is a well-known master regulator. Collectively, B cell reprogramming for differentiation and immune memory appears to be hallmarked by non-canonical TFEB signals.